Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 587

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 587
---
 States. To the extent that Cara raises additional capital through the future sale of equity or convertible debt, the ownership interest of its stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of Cara’s existing common stockholders. If Cara raises additional funds through

<div align='center'>336</div>

TABLE OF CONTENTS

the issuance of debt securities, these securities could contain covenants that would restrict Cara’s operations. If Cara raises additional funds through collaboration arrangements in the future, Cara may have to relinquish valuable rights to its technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to Cara.

### Sources of Liquidity
Since Cara’s inception to date, Cara has raised an aggregate of $943.8 million to fund its operations, including (1) net proceeds of $447.4 million from the sale of shares of its common stock in five public offerings, including Cara’s initial public offering; as well as the sale of its common stock under its open market sales agreement in 2023; (2) proceeds of $73.3 million from the sale of shares of Cara’s convertible preferred stock and from debt financings prior to its initial public offering; (3) $258.8 million under Cara’s license and supply agreements (including commercial supply sales and royalty payments), primarily with CSL Vifor, Maruishi, CKDP, and an earlier product candidate for which development efforts ceased in 2007; (4) Cara’s share of the profit generated by KORSUVA injection sales of $29.8 million; (5) net proceeds of $98.0 million from the purchase of Cara’s common stock in relation to the license agreements with CSL Vifor; and (6) net proceeds of $36.5 million from the sale of future ex-U.S. royalties and milestones to HCR under Cara’s agreements with CSL Vifor and Maruishi (see Note 12 of Cara’s Notes to Condensed Consolidated Financial Statements as of September 30, 2024, Collaboration and Licensing Agreements , included elsewhere in this proxy statement/prospectus).

On June 14, 2024, Cara’s approved a streamlined operating plan exploring strategic alternatives focused on maximizing shareholder value after Cara announced its decision to discontinue the clinical program in NP following the outcome from the dose-finding Part A of the KOURAGE-1 study evaluating the efficacy and safety of oral difelikef